curacle co., ltd.
A clinical-stage biopharma developing drugs for intractable vascular diseases.
365270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7365270008
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 서초구 효령로 23-1, 서울특별시
- Website:
- http://www.curacle.com/eng/main/
Description
Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-08-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.1 KB | ||
| 2022-07-29 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 159.6 KB | ||
| 2022-07-22 00:00 |
임시주주총회결과
|
Korean | 8.0 KB | ||
| 2022-07-07 00:00 |
투자판단관련주요경영사항(당뇨병성 신증 치료제 CU01-1001의 식품의약품안전처 2b상 임상시험계획(IND) 승인)
|
Korean | 10.8 KB | ||
| 2022-07-07 00:00 |
주주총회소집공고
|
Korean | 57.3 KB | ||
| 2022-07-07 00:00 |
의결권대리행사권유참고서류
|
Korean | 32.6 KB | ||
| 2022-06-27 00:00 |
투자판단관련주요경영사항(CU06-1004의 약동학적 특성 및 안전성/내약성을 평가하기 위한 미국 제1상 임상시험 결과)
|
Korean | 13.4 KB | ||
| 2022-06-27 00:00 |
기업설명회(IR)개최
|
Korean | 6.7 KB | ||
| 2022-06-09 00:00 |
주주총회소집결의(임시주주총회)
|
Korean | 8.1 KB | ||
| 2022-06-09 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.5 KB | ||
| 2022-05-16 00:00 |
분기보고서 (2022.03)
|
Korean | 642.7 KB | ||
| 2022-04-26 00:00 |
투자판단관련주요경영사항(당뇨병성 신증 치료제 CU01-1001의 식품의약품안전처 2b상 임상시험계획(IND) 신청)
|
Korean | 10.1 KB | ||
| 2022-04-19 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.5 KB | ||
| 2022-04-19 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.1 KB | ||
| 2022-04-19 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.3 KB |
Automate Your Workflow. Get a real-time feed of all curacle co., ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for curacle co., ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for curacle co., ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
